Overview of ARC
ARC aims to achieve improved performance of the supply chain in Africa to increase the availability of medicines and health commodities at the last mile by building efficient, effective and resilient supply chain systems. ARC’s approach is to be a connector, broker, trusted advisor, catalyst and ‘pace setter’ of supply chain transformation for Ministries of Health and their partners. ARC is an independent organization (defined as having no specific vested interests and being solution/ provider agnostic).
ARC’s Theory of Change centres on brokering, matching and structuring demand from MoH and Donors with supply of expertise, tools and best practices. This will be achieved through partnerships with private sector organisations and academia to build the capacity of Ministries of Health.
ARC is a non-profit organization registered in South Africa, with regional offices in Nigeria and Senegal and a growing presence in East Africa. The Southern Africa regional office is also building a centralized “Support Centre”, which will help coordinate activities across regions and countries in Africa, and support global engagement with private sector and donor partners.
ARC now seeks to contract an experienced product lifecycle planning manager, to support the supply chain operations of a major change to the way that anti-retroviral therapy will be provided to patients in the South African public health system.” The requirement is for 12-15 months support, depending on start date and a level of effort of 80-100%. The role would suit an experienced supply chain manager with experience of product launch / lifecycle management and who combines the ability to advocate and plan for changes to established ways of working, as well as engage with data and analytics to support decision-making. The role will report to ARC’s South Africa Country Lead.
Dolutegravir is the latest generation compound for antiretroviral therapy with a high clinical profile with low side effects. It has a broad label that allows usage both at initiation of treatment and for long term chronic therapy. TLD is the fixed dose combination pill with Dolutegravir, available at a substantial discount to the current Efavirenz based treatment (TEE).
This has led our government partner to determine that they will transfer all TEE patients to TLD.
Given the number of patients on treatment, the transition from TEE to TLD is the largest switch over in the history of such programmes, thus requiring a comprehensive supply chain transition plan that ensures adequate availability of medicines for patients. In addition, the expected penetration of antiretroviral therapy is expected to increase in line with the “90/90/90” objective.
The role is thus to plan the introduction of TLD into the public health supply chain, while maintaining full availability.
The purpose of this project is to develop a methodology that defines the supply chain processes for how new products will be introduced into the healthcare system in South Africa.
The project will also take this a step further and define a specific supply chain launch plan for cutting over from TEE to TLD. The plan must include the optimal phase-in and phase-out period across all stock holding sites with the full switch over concluding within one year.
Roles & Responsibilities
Supply Chain, Operations, Data Analytics, Data Visualisation, Data Modelling, Simulation, Management Information Systems, Business Intelligence, Systems Integration, Business Analyst, Demand Planning, Demand Forecasting, Inventory Management, Product Lifecycle Management, Route to Market, Data Mining
Skills, Attributes & Characteristics
ARC is a start-up organization with substantial ambition and expectation to make significant impact to national systems in order to fundamentally change the way health is delivered on the continent. This is a unique and demanding opportunity to join an entrepreneurial, growing and purpose-driven team that share the mission of universal availability of medicines for all people in Africa.
Application Closing date: 26 October 2018